These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 25742985)

  • 1. Enhanced axonal metabolism during early natalizumab treatment in relapsing-remitting multiple sclerosis.
    Wiebenga OT; Klauser AM; Schoonheim MM; Nagtegaal GJ; Steenwijk MD; van Rossum JA; Polman CH; Barkhof F; Pouwels PJ; Geurts JJ
    AJNR Am J Neuroradiol; 2015 Jun; 36(6):1116-23. PubMed ID: 25742985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.
    Wiebenga OT; Schoonheim MM; Hulst HE; Nagtegaal GJ; Strijbis EM; Steenwijk MD; Polman CH; Pouwels PJ; Barkhof F; Geurts JJ
    AJNR Am J Neuroradiol; 2016 Jun; 37(6):1030-7. PubMed ID: 26965463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serial 1H-MRS in relapsing-remitting multiple sclerosis: effects of interferon-beta therapy on absolute metabolite concentrations.
    Schubert F; Seifert F; Elster C; Link A; Walzel M; Mientus S; Haas J; Rinneberg H
    MAGMA; 2002 Jun; 14(3):213-22. PubMed ID: 12098564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis.
    Khan O; Shen Y; Caon C; Bao F; Ching W; Reznar M; Buccheister A; Hu J; Latif Z; Tselis A; Lisak R
    Mult Scler; 2005 Dec; 11(6):646-51. PubMed ID: 16320723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging axonal damage of normal-appearing white matter in multiple sclerosis.
    Fu L; Matthews PM; De Stefano N; Worsley KJ; Narayanan S; Francis GS; Antel JP; Wolfson C; Arnold DL
    Brain; 1998 Jan; 121 ( Pt 1)():103-13. PubMed ID: 9549491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring interferon β treatment response with magnetic resonance spectroscopy in relapsing remitting multiple sclerosis.
    Yetkin MF; Mirza M; Dönmez H
    Medicine (Baltimore); 2016 Sep; 95(36):e4782. PubMed ID: 27603381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
    Brown JWL; Coles A; Horakova D; Havrdova E; Izquierdo G; Prat A; Girard M; Duquette P; Trojano M; Lugaresi A; Bergamaschi R; Grammond P; Alroughani R; Hupperts R; McCombe P; Van Pesch V; Sola P; Ferraro D; Grand'Maison F; Terzi M; Lechner-Scott J; Flechter S; Slee M; Shaygannejad V; Pucci E; Granella F; Jokubaitis V; Willis M; Rice C; Scolding N; Wilkins A; Pearson OR; Ziemssen T; Hutchinson M; Harding K; Jones J; McGuigan C; Butzkueven H; Kalincik T; Robertson N;
    JAMA; 2019 Jan; 321(2):175-187. PubMed ID: 30644981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis.
    Chard DT; Griffin CM; McLean MA; Kapeller P; Kapoor R; Thompson AJ; Miller DH
    Brain; 2002 Oct; 125(Pt 10):2342-52. PubMed ID: 12244090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corpus callosum axonal injury in multiple sclerosis measured by proton magnetic resonance spectroscopic imaging.
    Oh J; Pelletier D; Nelson SJ
    Arch Neurol; 2004 Jul; 61(7):1081-6. PubMed ID: 15262739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapsing-remitting multiple sclerosis: metabolic abnormality in nonenhancing lesions and normal-appearing white matter at MR imaging: initial experience.
    He J; Inglese M; Li BS; Babb JS; Grossman RI; Gonen O
    Radiology; 2005 Jan; 234(1):211-7. PubMed ID: 15528260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain tissue sodium concentration in multiple sclerosis: a sodium imaging study at 3 tesla.
    Inglese M; Madelin G; Oesingmann N; Babb JS; Wu W; Stoeckel B; Herbert J; Johnson G
    Brain; 2010 Mar; 133(Pt 3):847-57. PubMed ID: 20110245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of switching from glatiramer acetate 20 mg/daily to glatiramer acetate 40 mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study.
    Zivadinov R; Bergsland N; Hagemeier J; Tavazzi E; Ramasamy DP; Durfee J; Cherneva M; Carl E; Carl J; Kolb C; Hojnacki D; Weinstock-Guttman B
    J Neurol Sci; 2018 Apr; 387():152-156. PubMed ID: 29571854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopy.
    Ruiz-Peña JL; Piñero P; Sellers G; Argente J; Casado A; Foronda J; Uclés A; Izquierdo G
    BMC Neurol; 2004 Jun; 4():8. PubMed ID: 15191618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial proton MR spectroscopy of gray and white matter in relapsing-remitting MS.
    Kirov II; Tal A; Babb JS; Herbert J; Gonen O
    Neurology; 2013 Jan; 80(1):39-46. PubMed ID: 23175732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (1)H MR spectroscopy of the brain in multiple sclerosis subtypes with analysis of the metabolite concentrations in gray and white matter: initial findings.
    Sijens PE; Mostert JP; Oudkerk M; De Keyser J
    Eur Radiol; 2006 Feb; 16(2):489-95. PubMed ID: 16028056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proton MR spectroscopy of lesion evolution in multiple sclerosis: Steady-state metabolism and its relationship to conventional imaging.
    Kirov II; Liu S; Tal A; Wu WE; Davitz MS; Babb JS; Rusinek H; Herbert J; Gonen O
    Hum Brain Mapp; 2017 Aug; 38(8):4047-4063. PubMed ID: 28523763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects.
    González-Oria MC; Márquez-Coello M; Girón-Ortega JA; Argente J; Moya M; Girón-González JA
    J Neuroimmune Pharmacol; 2019 Sep; 14(3):413-422. PubMed ID: 30649665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolite changes in early relapsing-remitting multiple sclerosis. A two year follow-up study.
    Tiberio M; Chard DT; Altmann DR; Davies G; Griffin CM; McLean MA; Rashid W; Sastre-Garriga J; Thompson AJ; Miller DH
    J Neurol; 2006 Feb; 253(2):224-30. PubMed ID: 16307201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.